Market Overview:
The global pre-menstrual syndrome (PMS) market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The analgesics segment is expected to dominate the market in terms of revenue share, followed by oral contraceptive pills (OCPs), gonadotropin-releasing hormone (GnRH), antidepressants, ovarian suppressors and diuretics segments. The hospitals segment is estimated to account for a major share of the PMS market in 2018 and is projected to grow at a CAGR of 6.1%. North America dominates the global PMS market with a revenue share of more than 50% in 2018 and is projected to grow at a CAGR of 5.7%.
Product Definition:
Pre-menstrual syndrome (PMS) is a group of symptoms that occur before a woman's period. Symptoms can include mood swings, fatigue, bloating, and changes in appetite. PMS is important because it can affect a woman's quality of life.
Analgesics (Pain Killers):
Analgesics (painkillers) are drugs that dull the pain. The market for analgesics is expected to grow over the forecast period owing to increasing prevalence of chronic diseases such as osteoarthritis, rheumatoid arthritis and other autoimmune disorders. Increasing geriatric population base coupled with rising awareness about self-medication among patients is also a high impact rendering driver for this market during the forecast period.
Oral Contraceptive Pills (OCPs):
Oral contraceptive pills (OCPs) are a group of drugs used to prevent pregnancy. They may also be used to treat menstrual disorders but they have no effect on the ability of a man to produce sperm. The most common types of OCPs areethinyl estradiol and mestranol; others include norethindrone acetate, drospirenone, and progesterone.
Application Insights:
Based on application, the global market is segmented into hospitals, clinics and other medical facilities, and others. Hospitals held the largest share in 2017 owing to availability of advanced healthcare services for premenstrual syndrome patients. These are also likely to be the fastest-growing segments over the forecast period due to increasing awareness about effective treatment options for PMS at a global level.
Clinics/medical facilities are expected to witness significant growth over the forecast period owing to growing number of practitioners treating PMS as a private or personal health issue without referring them to hospitals or other medical centers. This approach has resulted in increased adoption of these products by women during their menstrual cycles leading up with their doctors visits every three months till they get cured from this disorder completely.
Others include online pharmacies.
Regional Analysis:
North America dominated the global pre-menstrual syndrome market in 2017. The presence of a large number of manufacturers and well-established healthcare infrastructure are some factors responsible for its dominance. In addition, the high adoption rate of new technologies and rising awareness about PMS symptoms are also contributing to its growth in this region.
Asia Pacific is expected to grow at a lucrative CAGR during the forecast period owing to increasing awareness about PMS among women as well as men, which is leading towards higher diagnosis rates. In addition, growing medical tourism due to low cost treatment & availability of skilled doctors will drive demand further in this region over the forecast period. Moreover, economic development coupled with improving living standards has led towards an increase in consumer spending on health care products & services such as contraceptives; thereby driving market growth across this region during the forecast period (2018 - 2030).
Growth Factors:
- Rising awareness about the condition and its symptoms
- Growing number of women who are affected by PMS
- Increasing demand for effective treatments for PMS
- Availability of a wide range of treatment options for PMS
- Growing research on the causes and effects of PMS
Scope Of The Report
Report Attributes
Report Details
Report Title
Pre-Menstrual Syndrome Market Research Report
By Type
Analgesics (Pain Killers), Oral Contraceptive Pills (OCPs), Gonadotropin-Releasing Hormone (GnRH), Antidepressants, Ovarian Suppressors, Diuretics, Benzodiazepines
By Application
Hospitals, Clinic, Others
By Companies
Alva-Amco Pharmacal Cos., Inc., Bayer, Inc., Chattem, Inc. (Sanofi), DEKK-TEC, Inc., G. R. Lane Health Products Ltd, McNeil Consumer Healthcare, MetP Pharma AG, Pherin Pharmaceuticals, Inc., Umecrine Mood AB, Novartis AG, GlaxoSmithKline Plc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
225
Number of Tables & Figures
158
Customization Available
Yes, the report can be customized as per your need.
Global Pre-Menstrual Syndrome Market Report Segments:
The global Pre-Menstrual Syndrome market is segmented on the basis of:
Types
Analgesics (Pain Killers), Oral Contraceptive Pills (OCPs), Gonadotropin-Releasing Hormone (GnRH), Antidepressants, Ovarian Suppressors, Diuretics, Benzodiazepines
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Alva-Amco Pharmacal Cos., Inc.
- Bayer, Inc.
- Chattem, Inc. (Sanofi)
- DEKK-TEC, Inc.
- G. R. Lane Health Products Ltd
- McNeil Consumer Healthcare
- MetP Pharma AG
- Pherin Pharmaceuticals, Inc.
- Umecrine Mood AB
- Novartis AG
- GlaxoSmithKline Plc
Highlights of The Pre-Menstrual Syndrome Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Analgesics (Pain Killers)
- Oral Contraceptive Pills (OCPs)
- Gonadotropin-Releasing Hormone (GnRH)
- Antidepressants
- Ovarian Suppressors
- Diuretics
- Benzodiazepines
- By Application:
- Hospitals
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pre-Menstrual Syndrome Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pre-menstrual syndrome (PMS) is a condition that affects women before their periods. It can include mood swings, bloating, cramps, headaches and fatigue.
Some of the major companies in the pre-menstrual syndrome market are Alva-Amco Pharmacal Cos., Inc., Bayer, Inc., Chattem, Inc. (Sanofi), DEKK-TEC, Inc., G. R. Lane Health Products Ltd, McNeil Consumer Healthcare, MetP Pharma AG, Pherin Pharmaceuticals, Inc., Umecrine Mood AB, Novartis AG, GlaxoSmithKline Plc.
The pre-menstrual syndrome market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pre-Menstrual Syndrome Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pre-Menstrual Syndrome Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pre-Menstrual Syndrome Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pre-Menstrual Syndrome Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pre-Menstrual Syndrome Market Size & Forecast, 2018-2028
4.5.1 Pre-Menstrual Syndrome Market Size and Y-o-Y Growth
4.5.2 Pre-Menstrual Syndrome Market Absolute $ Opportunity
Chapter 5 Global Pre-Menstrual Syndrome Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Pre-Menstrual Syndrome Market Size Forecast by Type
5.2.1 Analgesics (Pain Killers)
5.2.2 Oral Contraceptive Pills (OCPs)
5.2.3 Gonadotropin-Releasing Hormone (GnRH)
5.2.4 Antidepressants
5.2.5 Ovarian Suppressors
5.2.6 Diuretics
5.2.7 Benzodiazepines
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Pre-Menstrual Syndrome Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Pre-Menstrual Syndrome Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pre-Menstrual Syndrome Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pre-Menstrual Syndrome Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Pre-Menstrual Syndrome Analysis and Forecast
9.1 Introduction
9.2 North America Pre-Menstrual Syndrome Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Pre-Menstrual Syndrome Market Size Forecast by Type
9.6.1 Analgesics (Pain Killers)
9.6.2 Oral Contraceptive Pills (OCPs)
9.6.3 Gonadotropin-Releasing Hormone (GnRH)
9.6.4 Antidepressants
9.6.5 Ovarian Suppressors
9.6.6 Diuretics
9.6.7 Benzodiazepines
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Pre-Menstrual Syndrome Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Pre-Menstrual Syndrome Analysis and Forecast
10.1 Introduction
10.2 Europe Pre-Menstrual Syndrome Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Pre-Menstrual Syndrome Market Size Forecast by Type
10.6.1 Analgesics (Pain Killers)
10.6.2 Oral Contraceptive Pills (OCPs)
10.6.3 Gonadotropin-Releasing Hormone (GnRH)
10.6.4 Antidepressants
10.6.5 Ovarian Suppressors
10.6.6 Diuretics
10.6.7 Benzodiazepines
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Pre-Menstrual Syndrome Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Pre-Menstrual Syndrome Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Pre-Menstrual Syndrome Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Pre-Menstrual Syndrome Market Size Forecast by Type
11.6.1 Analgesics (Pain Killers)
11.6.2 Oral Contraceptive Pills (OCPs)
11.6.3 Gonadotropin-Releasing Hormone (GnRH)
11.6.4 Antidepressants
11.6.5 Ovarian Suppressors
11.6.6 Diuretics
11.6.7 Benzodiazepines
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Pre-Menstrual Syndrome Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Pre-Menstrual Syndrome Analysis and Forecast
12.1 Introduction
12.2 Latin America Pre-Menstrual Syndrome Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Pre-Menstrual Syndrome Market Size Forecast by Type
12.6.1 Analgesics (Pain Killers)
12.6.2 Oral Contraceptive Pills (OCPs)
12.6.3 Gonadotropin-Releasing Hormone (GnRH)
12.6.4 Antidepressants
12.6.5 Ovarian Suppressors
12.6.6 Diuretics
12.6.7 Benzodiazepines
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Pre-Menstrual Syndrome Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Pre-Menstrual Syndrome Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Pre-Menstrual Syndrome Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Pre-Menstrual Syndrome Market Size Forecast by Type
13.6.1 Analgesics (Pain Killers)
13.6.2 Oral Contraceptive Pills (OCPs)
13.6.3 Gonadotropin-Releasing Hormone (GnRH)
13.6.4 Antidepressants
13.6.5 Ovarian Suppressors
13.6.6 Diuretics
13.6.7 Benzodiazepines
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Pre-Menstrual Syndrome Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pre-Menstrual Syndrome Market: Competitive Dashboard
14.2 Global Pre-Menstrual Syndrome Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Alva-Amco Pharmacal Cos., Inc.
14.3.2 Bayer, Inc.
14.3.3 Chattem, Inc. (Sanofi)
14.3.4 DEKK-TEC, Inc.
14.3.5 G. R. Lane Health Products Ltd
14.3.6 McNeil Consumer Healthcare
14.3.7 MetP Pharma AG
14.3.8 Pherin Pharmaceuticals, Inc.
14.3.9 Umecrine Mood AB
14.3.10 Novartis AG
14.3.11 GlaxoSmithKline Plc
